Galectin Therapeutics (GALT) Expected to Release Quarterly Earnings on Thursday

Galectin Therapeutics (NASDAQ:GALT) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.09) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Galectin Therapeutics (NASDAQ:GALT) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). On average, analysts expect Galectin Therapeutics to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Galectin Therapeutics Trading Down 9.6%

Galectin Therapeutics stock opened at $3.12 on Tuesday. The stock has a 50-day moving average price of $3.53 and a 200 day moving average price of $2.99. Galectin Therapeutics has a 52 week low of $2.03 and a 52 week high of $7.13. The stock has a market cap of $205.48 million, a PE ratio of -7.61 and a beta of 0.41.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Zacks Research lowered shares of Galectin Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 13th. Weiss Ratings upgraded shares of Galectin Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 18th. Wall Street Zen raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, June 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of Galectin Therapeutics in a research note on Tuesday, June 23rd. One investment analyst has rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Galectin Therapeutics currently has an average rating of “Reduce” and an average target price of $11.00.

Insiders Place Their Bets

In related news, Director Harold H. Shlevin sold 22,268 shares of Galectin Therapeutics stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $5.04, for a total value of $112,230.72. Following the completion of the transaction, the director directly owned 6,500 shares in the company, valued at approximately $32,760. This trade represents a 77.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Khurram Jamil sold 47,467 shares of Galectin Therapeutics stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $5.04, for a total value of $239,233.68. Following the completion of the transaction, the insider owned 2,037 shares of the company’s stock, valued at approximately $10,266.48. The trade was a 95.89% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 90,162 shares of company stock worth $438,464. Corporate insiders own 52.60% of the company’s stock.

Institutional Investors Weigh In On Galectin Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC raised its position in shares of Galectin Therapeutics by 37.4% during the 4th quarter. Virtu Financial LLC now owns 53,551 shares of the company’s stock worth $223,000 after buying an additional 14,583 shares in the last quarter. Invesco Ltd. bought a new position in shares of Galectin Therapeutics in the fourth quarter valued at approximately $43,000. XTX Topco Ltd bought a new position in shares of Galectin Therapeutics in the fourth quarter valued at approximately $216,000. Wellington Management Group LLP acquired a new position in shares of Galectin Therapeutics during the fourth quarter valued at approximately $592,000. Finally, Millennium Management LLC increased its stake in shares of Galectin Therapeutics by 113.3% during the fourth quarter. Millennium Management LLC now owns 235,508 shares of the company’s stock valued at $980,000 after acquiring an additional 125,086 shares during the period. 11.68% of the stock is owned by institutional investors and hedge funds.

About Galectin Therapeutics

Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company’s lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.

Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.